CCR5 and HIV-1 infection: In patients with HIV-1 infection, maraviroc (a CCR5 antagonist) treatment was associated with reduced bone loss at the hip and lumbar spine compared to tenofovir disoproxil fumarate (TDF)-containing antiretroviral therapy (ART).88 These data suggest that CCR5 has a critical role in bone disorders through the functional regulation of osteoclasts.